Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy

Brittany M. Lee(Seattle Children's Hospital), Adam J. Lamble(Seattle Children's Hospital), Corinne Summers(Seattle Children's Hospital), Sandra D. Bohling(Seattle Children's Hospital), Kasey J. Leger, Colleen Annesley(Unknown), Rebecca Gardner(Seattle Children's Hospital), Karen M. Chisholm(Seattle Children's Hospital)
Blood Advances
February 10, 2023
10.1182/bloodadvances.2022009480
Cited by 16

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Current concepts in the diagnosis and management of cytokine release syndrome
|Blood|2014|2.8k
CD19 CAR T cell product and disease attributes predict leukemia remission durability
|Journal of Clinical Investigation|2019|355
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
|Nature Medicine|2021|319
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
|Blood|2019|287